Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.74 | 16.07 | 27.78 | 40.35 | 49.35 | 62.24 | 245.45 | 131.31 | 46.96 | 53.88 | 19.48 | 58.70 | 36.65 | 56.96 | 184.83 | 234.53 | 306.66 | — | — | 166.49 | 158.38 |
| — | -74.2% | -88.7% | -69.3% | +5.1% | +15.5% | +1160.1% | +123.7% | +28.1% | -5.4% | -89.5% | -75.0% | -88.0% | — | — | +40.9% | +93.6% | — | — | -97.7% | — | |
| P/S Ratio | 3.18 | 2.69 | 3.30 | 4.83 | 6.41 | 7.72 | 8.55 | 8.55 | 8.09 | 7.91 | 7.62 | 7.15 | 7.43 | 6.78 | 12.75 | 15.61 | 13.94 | 11.68 | 12.62 | 15.75 | 15.09 |
| — | -65.1% | -61.5% | -43.5% | -20.8% | -2.4% | +12.1% | +19.5% | +8.9% | +16.6% | -40.2% | -54.2% | -46.7% | -41.9% | +1.0% | -0.9% | -7.6% | -34.9% | -27.4% | -7.9% | -11.9% | |
| P/B Ratio | 6.95 | 5.74 | 7.43 | 11.31 | 13.26 | 15.76 | 15.17 | 14.63 | 15.96 | 15.40 | 14.92 | 15.98 | 20.69 | 19.33 | 36.51 | 44.47 | 43.27 | 37.21 | 35.78 | 41.66 | 33.39 |
| — | -63.6% | -51.0% | -22.7% | -17.0% | +2.4% | +1.7% | -8.5% | -22.8% | -20.4% | -59.1% | -64.1% | -52.2% | -48.1% | +2.0% | +6.7% | +29.6% | -6.4% | -10.3% | +41.4% | +19.6% | |
| P/FCF | 39.03 | 34.14 | 44.47 | 42.82 | 104.18 | 52.09 | 32.02 | 94.48 | 52.73 | 59.93 | 57.91 | 49.68 | 80.29 | 87.37 | 195.22 | — | — | 174.61 | 609.49 | — | — |
| — | -34.5% | +38.9% | -54.7% | +97.6% | -13.1% | -44.7% | +90.2% | -34.3% | -31.4% | -70.3% | — | — | -50.0% | -68.0% | — | — | — | — | — | — | |
| EV / EBITDA | 15.77 | 12.47 | 17.55 | 25.62 | 29.91 | 39.53 | 39.43 | 44.97 | 37.86 | 40.47 | 52.83 | 44.07 | 31.86 | 42.80 | 107.04 | 129.37 | 134.90 | 221.54 | — | 90.77 | 73.80 |
| — | -68.4% | -55.5% | -43.0% | -21.0% | -2.3% | -25.4% | +2.0% | +18.8% | -5.4% | -50.6% | -65.9% | -76.4% | -80.7% | — | +42.5% | +82.8% | +111.3% | — | -39.6% | -68.1% | |
| EV / EBIT | 22.12 | 12.47 | 20.76 | 29.76 | 31.95 | 39.90 | 117.80 | 86.71 | 41.27 | 46.50 | 62.70 | 50.85 | 34.84 | 49.07 | 137.86 | 170.85 | 176.17 | 1189.97 | — | 129.81 | 99.95 |
| — | -68.7% | -82.4% | -65.7% | -22.6% | -14.2% | +87.9% | +70.5% | +18.5% | -5.2% | -54.5% | -70.2% | -80.2% | -95.9% | — | +31.6% | +76.3% | +622.8% | — | -61.1% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.6% | 75.1% | 70.2% | 69.5% | 72.5% | 72.2% | 69.7% | 71.9% | 72.1% | 69.3% | 67.7% | 69.5% | 70.9% | 67.8% | 66.8% | 67.2% | 58.8% | 55.3% | 63.6% | 71.0% | 69.3% |
| — | +3.9% | +0.7% | -3.4% | +0.6% | +4.2% | +2.8% | +3.5% | +1.8% | +2.3% | +1.4% | +3.4% | +20.5% | +22.7% | +5.1% | -5.4% | -15.2% | -19.3% | -8.4% | +6.9% | +5.8% | |
| Operating Margin | 17.5% | 22.5% | 16.2% | 16.0% | 18.7% | 16.7% | 18.7% | 15.6% | 18.3% | 16.2% | 11.2% | 12.9% | 20.9% | 12.7% | 7.8% | 7.7% | 6.4% | 0.9% | -8.9% | 12.8% | 16.2% |
| — | +35.3% | -13.3% | +2.7% | +2.0% | +2.9% | +67.2% | +21.1% | -12.4% | +27.9% | +42.2% | +66.5% | +228.3% | +1388.4% | +188.0% | -39.7% | -60.6% | -93.0% | -189.2% | +98.6% | +644.5% | |
| Net Margin | 9.1% | 16.8% | 11.8% | 12.0% | 13.0% | 12.4% | 3.5% | 6.2% | 16.9% | 14.2% | 38.6% | 11.7% | 20.3% | 12.0% | 6.9% | 6.6% | 4.6% | -1.5% | -11.7% | 9.4% | 9.5% |
| — | +35.1% | +241.9% | +92.2% | -23.1% | -13.0% | -91.0% | -46.6% | -16.8% | +18.8% | +460.7% | +75.4% | +340.7% | +886.1% | +158.9% | -29.4% | -51.5% | -133.4% | -23.1% | +3857.5% | +236.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.1% | 9.4% | 7.0% | 6.5% | 7.0% | 6.2% | 1.6% | 2.8% | 8.6% | 7.3% | 21.1% | 6.8% | 15.4% | 8.9% | 5.2% | 4.9% | 3.8% | -1.2% | -8.1% | 5.5% | 5.5% |
| — | +52.8% | +332.9% | +132.2% | -18.9% | -16.0% | -92.4% | -58.8% | -43.9% | -18.1% | +308.0% | +39.1% | +310.1% | +830.8% | +164.2% | -12.3% | -32.1% | -146.4% | -68.2% | +5394.0% | +294.2% | |
| ROA | 7.9% | 4.3% | 3.1% | 2.9% | 3.3% | 2.7% | 0.6% | 1.1% | 3.3% | 2.6% | 6.9% | 2.0% | 4.1% | 2.1% | 1.2% | 1.0% | 0.8% | -0.2% | -1.7% | 1.4% | 1.4% |
| — | +59.1% | +379.5% | +175.2% | -0.8% | +2.7% | -90.6% | -45.8% | -19.4% | +22.7% | +486.6% | +88.5% | +430.9% | +980.1% | +169.8% | -22.4% | -46.7% | -137.8% | -26.0% | +4080.2% | +251.2% | |
| ROIC | 20.1% | 7.5% | 5.4% | 5.1% | 6.3% | 5.0% | 5.0% | 3.9% | 5.0% | 4.0% | 2.6% | 2.8% | 5.4% | 2.9% | 1.7% | 1.6% | 1.4% | 0.2% | -1.7% | 2.6% | 3.8% |
| — | +50.8% | +7.8% | +30.0% | +25.7% | +24.1% | +94.4% | +38.0% | -7.1% | +38.7% | +53.2% | +81.0% | +272.3% | +1454.9% | +197.7% | -39.6% | -61.8% | -93.4% | -173.8% | +69.2% | +599.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | 0.61 | 0.67 | 0.73 | 0.69 | 0.75 | 0.97 | 1.27 | 1.17 | 1.25 | 1.40 | 1.77 | 1.98 | 2.34 | 2.52 | 2.78 | 3.01 | 3.29 | 3.34 | 3.17 | 2.31 |
| — | -18.2% | -31.2% | -42.9% | -40.9% | -40.4% | -30.8% | -28.1% | -40.6% | -46.5% | -44.5% | -36.2% | -34.3% | -28.9% | -24.5% | -12.4% | +30.1% | +27.3% | +22.1% | +73.9% | +29.7% | |
| Debt / EBITDA | 1.86 | 5.08 | 6.06 | 6.39 | 6.16 | 7.38 | 9.88 | 15.34 | 10.87 | 12.78 | 18.97 | 18.51 | 11.57 | 19.33 | 28.41 | 31.10 | 36.09 | 74.82 | — | 26.62 | 19.91 |
| — | -31.2% | -38.7% | -58.3% | -43.4% | -42.2% | -47.9% | -17.1% | -6.1% | -33.9% | -33.2% | -40.5% | -67.9% | -74.2% | — | +16.8% | +81.2% | +180.5% | — | -27.4% | -66.0% | |
| Current Ratio | 2.78 | 2.51 | 2.48 | 2.49 | 2.78 | 2.87 | 2.23 | 4.43 | 3.54 | 3.64 | 3.56 | 3.70 | 3.47 | 3.22 | 3.31 | 3.43 | 3.56 | 3.93 | 4.64 | 5.92 | 5.75 |
| — | -12.7% | +11.2% | -43.9% | -21.6% | -21.1% | -37.3% | +19.7% | +2.0% | +12.9% | +7.7% | +8.0% | -2.5% | -18.1% | -28.7% | -42.0% | -38.1% | -30.5% | -20.3% | -7.0% | -3.4% | |
| Quick Ratio | 2.11 | 1.83 | 1.83 | 1.81 | 2.11 | 2.18 | 1.79 | 3.59 | 2.73 | 2.76 | 2.68 | 2.71 | 2.58 | 2.31 | 2.34 | 2.42 | 2.61 | 2.95 | 3.49 | 4.45 | 4.43 |
| — | -16.2% | +2.3% | -49.4% | -22.6% | -20.9% | -33.0% | +32.4% | +5.7% | +19.3% | +14.4% | +11.9% | -1.2% | -21.7% | -33.0% | -45.6% | -41.1% | -34.8% | -28.6% | -18.3% | -15.1% | |
| Interest Coverage | 5.26 | 15.64 | 9.79 | 8.69 | 8.15 | 8.87 | 2.45 | 6.23 | 13.79 | 7.74 | 5.65 | 6.13 | 17.09 | 6.16 | 3.94 | 3.62 | 3.30 | 0.38 | -3.08 | 4.13 | 3.16 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PODD stock.
Insulet Corp.'s current P/E is 23.7x. The average P/E over the last 4 quarters is 33.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Insulet Corp.'s current operating margin is 17.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Insulet Corp.'s business trajectory between earnings reports.